Lung specific expression of a human mutant p53 affects cell proliferation in transgenic mice (original) (raw)

References

• Alberg AJ, Brock MV, Samet JM (2005) Epidemiology of lung cancer: looking to the future. J Clin Oncol 23:3175–3185
  Article PubMed Google Scholar
• Albor A, Kaku S, Kulesz-Martin M (1998) Wild-type and mutant forms of p53 activate human topoisomerase I: a possible mechanism for gain of function in mutants. Cancer Res 58:2091–2094
  PubMed CAS Google Scholar
• Bargonetti J, Reynisdottir I, Friedman PN, Prives C (1992) Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. Genes Dev 6:1886–1898
  Article PubMed CAS Google Scholar
• Blandino G, Levine AJ, Oren M (1999) Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18:477–485
  Article PubMed CAS Google Scholar
• Brugarolas J, Chandrasekaran C, Gordon JL, Beach D, Jacks T, Hannon GJ (1995) Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377:552–557
  Article PubMed CAS Google Scholar
• Burns TF, Bernhard EJ, El-Deiry WS (2001) Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in _p53_-dependent apoptosis in vivo. Oncogene 20:4601–4612
  Article PubMed CAS Google Scholar
• Cayrol C, Knibiehler M, Ducommun B (1998) p21 binding to PCNA causes G1 and G2 cell cycle arrest in _p53_-deficient cells. Oncogene 16:311–320
  Article PubMed CAS Google Scholar
• Cho Y, Gorina S, Jeffrey PD, Pavletich NP (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265:346–355
  Article PubMed CAS Google Scholar
• D’Amico D, Carbone D, Mitsudomi T, Nau M, Fedorko J, Russell E, Johnson B, Buchhagen D, Bodner S, Phelps R, Gazdar A, Minna JD (1992) High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene 7:339–346
  PubMed CAS Google Scholar
• Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ (1993) Gain of function mutations in p53. Nat Genet 4:42–46
  Article PubMed CAS Google Scholar
• Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215–221
  Article PubMed CAS Google Scholar
• Duan W, Ding H, Subler MA, Zhu WG, Zhang H, Stoner GD, Windle JJ, Otterson GA, Villalona-Calero MA (2002a) Lung-specific expression of human mutant _p53_-273H is associated with a high frequency of lung adenocarcinoma in transgenic mice. Oncogene 21:7831–7838
  Article PubMed CAS Google Scholar
• Duan W, Ding H, Zhu WG, Srinivasan K, Ottersom GA, Villalona-Calero MA (2002b) RT-PCR heteroduplex analysis permits differentiation of transgene and host gene expression in a transgenic animal model. Biotechniques 33:58–66
  PubMed CAS Google Scholar
• El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817–825
  Article PubMed CAS Google Scholar
• El-Hizawi S, Lagowski JP, Kulesz-Martin M, Albor A (2002) Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins. Cancer Res 62:3264–3270
  PubMed CAS Google Scholar
• Engel FB, Hauck L, Boehm M, Nabel EG, Dietz R, von Harsdorf R (2003) p21(CIP1) Controls proliferating cell nuclear antigen level in adult cardiomyocytes. Mol Cell Biol 23:555–565
  Article PubMed CAS Google Scholar
• Glasser SW, Burhans MS, Eszterhas SK, Bruno MD, Korfhagen TR (2000) Human SP-C gene sequences that confer lung epithelium-specific expression in transgenic mice. Am J Physiol Lung Cell Mol Physiol 278:L933–L945
  PubMed CAS Google Scholar
• Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805–816
  Article PubMed CAS Google Scholar
• Kawamura M, Yamashita T, Segawa K, Kaneuchi M, Shindoh M, Fujinaga K (1996) The 273rd codon mutants of p53 show growth modulation activities not correlated with _p53_-specific transactivation activity. Oncogene 12:2361–2367
  PubMed CAS Google Scholar
• Kern SE, Pietelpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B (1992) Oncogenic forms of p53 inhibit _p53_-regulated gene expression. Science 256:827–830
  Article PubMed CAS Google Scholar
• Ko JL, Prives C (1996) p53: puzzle and paradigm. Genes Dev 10:1054–1072
  Article PubMed CAS Google Scholar
• Korfhagen TR, Glasser SW, Wert SE, Bruno MD, Daugherty CC, McNeish JD, Stock JL, Potter SS, Whitsett JA (1990) Cis-acting sequences from a human surfactant protein gene confer pulmonary-specific gene expression in transgenic mice. Proc Natl Acad Sci USA 87:6122–6126
  Article PubMed CAS Google Scholar
• Martin-Caballero J, Flores JM, Garcia-Palencia P, Serrano M (2001) Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res 61:6234–6238
  PubMed CAS Google Scholar
• Milner J, Medcalf EA, Cook AC (1991) Tumor suppressor p53: analysis of wild-type and mutant p53 complexes. Mol Cell Biol 11:12–19
  PubMed CAS Google Scholar
• Mitsudomi T, Steinberg SM, Nau MM, Carbone D, D’Amico D, Bodner S, Oie HK, Linnoila RI, Mulshine JL, Minna JD (1992) p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7:171–180
  PubMed CAS Google Scholar
• Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T (2004) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119:847–860
  Article PubMed CAS Google Scholar
• Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P (2002) The IARC TP53 Database: new online mutation analysis and recommendations to users. Hum Mutat 19:607–614
  Article PubMed CAS Google Scholar
• Park DJ, Nakamura H, Chumakov AM, Said JW, Miller CW, Chen DL, Koeffler HP (1994) Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines. Oncogene 9:1899–1906
  PubMed CAS Google Scholar
• Paunesku T, Mittal S, Protic M, Oryhon J, Korolev SV, Joachimiak A, Woloschak GE (2001) Proliferating cell nuclear antigen (PCNA): ringmaster of the genome. Int J Radiat Biol 77:1007–1021
  Article PubMed CAS Google Scholar
• Sigal A, Rotter V (2000) Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60:6788–6793
  PubMed CAS Google Scholar
• Vairapandi M, Azam N, Balliet AG, Hoffman B, Liebermann DA (2000) Characterization of MyD118, Gadd45, and proliferating cell nuclear antigen (PCNA) interacting domains. PCNA impedes MyD118 AND Gadd45-mediated negative growth control. J Biol Chem 275:16810–16819
  Article PubMed CAS Google Scholar
• van Oijen MG, Slootweg PJ (2000) Gain-of-function mutations in the tumor suppressor gene p53. Clin Cancer Res 6:2138–2145
  PubMed Google Scholar
• Wu L, Bayle JH, Elenbaas B, Pavletich NP, Levine AJ (1995) Alternatively spliced forms in the carboxy-terminal domain of the p53 protein regulate its ability to promote annealing of complementary single strands of nucleic acids. Mol Cell Biol 15:497–504
  PubMed CAS Google Scholar
• Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366:701–704
  Article PubMed CAS Google Scholar
• Xu J, Morris GF (1999) _p53_-mediated regulation of proliferating cell nuclear antigen expression in cells exposed to ionizing radiation. Mol Cell Biol 19:12–20
  PubMed Google Scholar
• Zhang W, Funk WD, Wright WE, Shay JW, Deisseroth AB (1993) Novel DNA binding of p53 mutants and their role in transcriptional activation. Oncogene 8:2555–2559
  PubMed CAS Google Scholar

Download references